Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ODI Pharma ABXSAT:ODI -6.56%45 EPS without NRI is kr-0.01 as of Mar. 2026. GuruFocus rates XSAT:ODI with a GF Score™ of 45/100 and a GF Value™ of kr9.59 (Significantly Undervalued). Among 789 Drug Manufacturers companies, ODI Pharma AB ranks better than 56.27% on this metric.
ODI Pharma AB's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was kr0.01.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.01.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 12.60% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 21.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for ODI Pharma AB's EPS without NRI or its related term are showing as below:
XSAT:ODI'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.3 Med: 2.45 Max: 57.5
Current: 12.6
During the past 7 years, ODI Pharma AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 57.50% per year. The lowest was -26.30% per year. And the median was 2.45% per year.
XSAT:ODI's 3-Year EPS without NRI Growth Rate is ranked better than 56.27% of 789
companies
in the Drug Manufacturers industry
Industry Median: 9.6
vs XSAT:ODI: 12.60
ODI Pharma AB's EPS (Diluted) for the
three
months ended in Mar. 2026 was kr0.01.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.01.
ODI Pharma AB's EPS (Basic) for the
three
months ended in Mar. 2026 was kr0.01.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.01.
ODI Pharma AB (XSAT:ODI) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
ODI Pharma AB EPS without NRI Related Terms
ODI Pharma AB EPS without NRI Historical Data
* Premium members only.
The historical data trend for ODI Pharma AB's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:ODI vs ZTS, UTHR, VTRS: EPS without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ODI Pharma AB PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where ODI Pharma AB's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ODI Pharma AB (XSAT:ODI) has a EPS without NRI of kr-0.01 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on ODI Pharma AB and its competitors. According to the industry distribution chart, ODI Pharma AB ranks #345 out of 789 companies in the Drug Manufacturers industry, placing it in the top 43.7%.
Is ODI Pharma AB's EPS without NRI too high?
ODI Pharma AB's current EPS without NRI is kr-0.01. Based on the distribution chart, ODI Pharma AB ranks #345 out of 789 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ODI Pharma AB has a GF Score™ of 45/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ODI Pharma AB ranks #345 out of 789 companies for EPS without NRI. This puts ODI Pharma AB in the upper half of its industry. The industry median EPS without NRI is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 789 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on ODI Pharma AB and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ODI Pharma AB's current EPS without NRI is kr-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.59, compared to a current price of kr2.28 — trading 76.2% below its estimated fair value. The current EPS without NRI is kr-0.01. ODI Pharma AB's overall GF Score™ is 45/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current EPS without NRI is kr-0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?
Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued.
The current stock price of kr2.28 is trading 76.2% below its estimated GF Value™ of kr9.59.
GuruFocus considers ODI Pharma AB to be Significantly Undervalued.
Key valuation signals for XSAT:ODI:
EPS without NRI: kr-0.01
GF Value™: kr9.59 vs. price of kr2.28 (76.2% below fair value)
No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ODI has been successfully added to your 
